Jefferies initiated coverage of Candel Therapeutics Inc (CADL) at Buy on October 22, 2026.
Three of three firms active in the past 90 days rate the stock in the bullish tier. The consensus price targets from 10 analysts as of October 30, 2026, have a mean of $23.33, a median of $24.48 and a range of $15.15 to $30.45.
For Q4 FY2026, analysts expect EPS of -$0.38 and revenue of $0. The next earnings report is scheduled for March 10, 2027.
